Eagle Pharmaceuticals, Inc. Net Change in Cash
Eagle Pharmaceuticals, Inc. reported Net Change in Cash of -$39.97 million for the 6-month period ending 2023-06-30, per its 10-Q/A filed 2023-08-09.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2023-08-09
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$33.42M.
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$28.14M, a 1456.65% decline year-over-year.
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was $2.07M, a 97.75% decline year-over-year.
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $92.24M, a 295.07% increase year-over-year.
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$42.34M.
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was -$5.50M.
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was -$6.62M, a 121.37% decline from fiscal 2019.
- Eagle Pharmaceuticals, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was $30.98M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-06-30 | -$39.97M 10-Q/A · filed 2023-08-09 | |||
| 2023-03-31 | -$33.42M 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | -$42.34M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | -$82.28M 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | -$61.10M 10-Q/A · filed 2023-08-09 | |||
| 2022-03-31 | -$28.14M 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | -$5.50M 10-K · filed 2023-03-23 | |||
| 2021-09-30 | -$3.41M 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | $5.56M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $2.07M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | -$6.62M 10-K · filed 2023-03-23 | |||
| 2020-09-30 | -$20.09M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | -$1.56M 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | $92.24M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $30.98M 10-K · filed 2022-03-08 | |||
| 2019-09-30 | $38.42M 10-Q · filed 2020-11-02 | |||
| 2019-06-30 | $29.34M 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | $23.35M 10-Q · filed 2020-05-11 | |||
| 2018-12-31 | -$35.87M 10-K · filed 2021-03-05 | |||
| 2018-09-30 | -$23.43M 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | -$14.41M 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | -$18.99M 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $61.84M 10-K · filed 2020-03-02 |